Vetex Medical
Financials
Estimates*
EUR | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|
EBITDA | (1.1m) | <1m | (<1m) | (1.3m) |
Profit | (1.1m) | <1m | (<1m) | (1.3m) |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | Grant | |
€2.5m | Grant | ||
$39.9m Valuation: $39.9m -51.9x EV/LTM EBITDA | Acquisition | ||
Total Funding | €2.5m |
Recent News about Vetex Medical
EditVetex Medical is a forward-thinking startup based in Ireland, specializing in the development of innovative catheters designed to treat Venous Thrombus Embolism (VTE). VTE is a condition where blood clots form in the veins, which can lead to serious health issues. The company’s primary product is the Vetex Thrombectomy Catheter, a device engineered to effectively and efficiently remove these clots, thereby improving clinical outcomes and enhancing the quality of life for patients.
Vetex Medical operates in the medical technology market, specifically focusing on venous clot management solutions. Their clientele includes healthcare providers such as hospitals and clinics, as well as physicians who specialize in treating venous diseases. The company’s team comprises interventionalists, engineers, scientists, and regulatory experts, all committed to bringing innovative solutions to both physicians and patients.
The business model of Vetex Medical revolves around the research, development, and commercialization of their thrombectomy catheter. They generate revenue by selling these medical devices to healthcare institutions and professionals. Additionally, they may engage in partnerships or collaborations with other medical companies to expand their market reach and enhance their product offerings.
In summary, Vetex Medical is dedicated to improving patient outcomes through innovative medical technology designed to manage and treat venous thromboembolism. By focusing on effective and efficient solutions, they aim to set new standards in the field of venous disease treatment.
Keywords: Venous Thrombus Embolism, VTE, Thrombectomy Catheter, Clot Management, Deep Vein Thrombosis, Medical Technology, Healthcare, Innovation, Patient Outcomes, Ireland.